semaglutide oral contraceptive pharmacokinetics Semaglutide, a once‐weekly human GLP‐1 analog, does not reduce the bioavailability of the combined contraceptive, ethinylestradiol/levonorgestrel - Kapitza - 2015 - The Journal of Clinical Pharmacology Semaglutide, a once‐weekly human GLP‐1
Description
As an internal medicine physician, I spent years prioritizing my patients'...
GLP-1s will remake CKD care.
Among patients who discontinued, the cumulative incidence of treatment reinitiation was 41.1% at 1 year and 57.4% at 3 years after discontinuation
On March 24, 2023 Novo Nordisk announced that oral semaglutide 25 mg and 50 mg (investigated in the PIONEER PLUS phase 3 trial) showed superior reductions in HbA1c and body weight vs
I distinctly recall this episode
